» Articles » PMID: 26704693

Safety and Efficacy of Ledipasvir/sofosbuvir for the Treatment of Genotype 1 Hepatitis C in Subjects Aged 65 Years or Older

Overview
Journal Hepatology
Specialty Gastroenterology
Date 2015 Dec 26
PMID 26704693
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: Elderly subjects have been historically underrepresented in clinical trials involving antiviral hepatitis C therapies. The aim of this analysis was to retrospectively evaluate the safety and efficacy of ledipasvir/sofosbuvir (LDV/SOF) by age groups of <65 years versus ≥65 years among subjects enrolled in phase 3 trials. Four open-label phase 3 clinical trials evaluated the safety and efficacy of LDV/SOF with or without ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C virus. Sustained virological response at 12 weeks, treatment-emergent adverse events (AEs), and graded laboratory abnormalities were analyzed according to age group. Of the 2293 subjects enrolled in four phase 3 trials, 264 (12%) were ≥65 years of age, of whom 24 were aged ≥75 years. Sustained virological response at 12 weeks was achieved by 97% (1965/2029) of subjects aged <65 years and 98% (258/264) of subjects aged ≥65 years. The most common AEs in both LDV/SOF groups that occurred in ≥10% of subjects were headache and fatigue. The rate of study discontinuation due to AEs was similar in the two age cohorts. The use of RBV in 1042 (45%) subjects increased the number of AEs, treatment-related AEs, and AEs leading to study drug modification/interruption, particularly among elderly subjects.

Conclusions: LDV/SOF with or without RBV was highly effective for treatment of genotype 1 chronic hepatitis C virusin subjects aged 65 and older. Addition of RBV did not increase sustained virological response at 12 weeks rates but led to higher rates of AEs, especially in elderly subjects.

Citing Articles

Chronic Hepatitis C: Acute Exacerbation and Alanine Aminotransferase Flare.

Kanda T, Matsumoto N, Ishii T, Arima S, Shibuya S, Honda M Viruses. 2023; 15(1).

PMID: 36680223 PMC: 9861769. DOI: 10.3390/v15010183.


Real-life experience of ledipasvir and sofosbuvir for HCV infected Korean patients: a multicenter cohort study.

Lee S, Lee S, Lee H, Kim H, Kim C, Song D Korean J Intern Med. 2022; 37(6):1167-1175.

PMID: 35618302 PMC: 9666263. DOI: 10.3904/kjim.2022.013.


Efficacy and safety of glecaprevir and pibrentasvir in Japanese patients with hepatitis C virus infection aged 75 years or older.

Komaki Y, Ozono Y, Nakamura K, Iwakiri H, Hasuike S, Sueta M BMC Gastroenterol. 2022; 22(1):210.

PMID: 35484503 PMC: 9052496. DOI: 10.1186/s12876-022-02284-z.


Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis.

Yang X, Tang Y, Xu D, Zhang G, Xu P, Tang H Virol J. 2021; 18(1):156.

PMID: 34315488 PMC: 8314543. DOI: 10.1186/s12985-021-01625-w.


Direct-acting antiviral treatment for Hepatitis C Virus in geriatric patients: a real-world retrospective comparison between early and late elderly patients.

Yen H, Su P, Liu I, Zeng Y, Huang S, Hsu Y PeerJ. 2021; 9:e10944.

PMID: 33777520 PMC: 7977377. DOI: 10.7717/peerj.10944.